Calpro
- Company typePrivate
- Founded1993
- HeadquartersLysaker, Norway
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Calpro firmographics
Firmographics- Name
- Calpro
- Legal name
- Calpro AS
- Website
- https://calpro.no
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Calpro industry classification
Industry- Product category
- In Vitro Diagnostics for Inflammatory Bowel Disease (Calprotectin Testing)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
- akta.pro secondary industry
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where Calpro is headquartered
LocationHeadquarters
- HQ city
- Lysaker
- HQ country
- Norway
- HQ region
- Europe
Offices3 records
Markets served
Calpro business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Test Kits and Laboratory Assays: Sale of CalproSmart rapid test kits (Self-Test, Office, RUO variants) and CalproLab ELISA assay kits (ALP and HRP formats, including RUO versions). Products are sold as complete kits including all required components. One-time purchase model per kit/order. Distribution via direct sales (UK) and regional distributors (Europe, Middle East, Africa, Asia-Pacific).
- Easy Extract Extraction Devices: Sale of Calpro Easy Extract prefilled extraction devices. Consumable product supporting the calprotectin testing workflow. Sold as 50-unit packs. Complements ELISA kit sales and supports home sampling workflows.
- CalproSmart Digital Services and Integration: CalproSmart app-based monitoring service with secure cloud backend. API and DeepLink integration services for HIS/LIMS connectivity. Clinic portal for device and patient management. Revenue derived from connected testing ecosystem supporting the device kit sales.
- Distribution Partnerships: Partnership with pharmaceutical companies requiring robust calprotectin biomarker tools for clinical trials and research. Sale of RUO (Research Use Only) products for pharmaceutical partner biomarker programs and clinical study deployments.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Calpro product offering
Product offeringCore offering
Calpro develops, manufactures, and distributes CE/IVD-marked calprotectin diagnostic test kits and a connected digital ecosystem for inflammatory bowel disease (IBD). The portfolio includes laboratory ELISA kits (CalproLab ALP and HRP), point-of-care rapid tests (CalproSmart Office), home self-tests (CalproSmart Self-Test), research-use-only variants, a prefilled stool extraction device (Calpro Easy Extract), and the CalproSmart digital platform (app, cloud backend, API, and DeepLink integration to HIS/LIMS). Products deliver quantitative fecal calprotectin results in under 20 minutes across the full IBD care pathway.
Product overview
Calpro offers a comprehensive portfolio of calprotectin-based diagnostic solutions spanning from laboratory ELISA assays to point-of-care and home monitoring. The portfolio includes CalproSmart Self-Test for patient home monitoring with smartphone app connectivity, CalproSmart Office for rapid point-of-care testing, CalproSmart RUO for research applications, CalproLab ELISA kits (ALP and HRP variants) for high-precision laboratory testing, CalproLab ELISA RUO for research use, and Calpro Easy Extract sample preparation devices. The ecosystem is unified through CalproSmart Services providing API and DeepLink integration connecting patient self-test data to clinical systems and enabling remote monitoring workflows.
Differentiator
Problem solved
Functional benefit
Brands
- CalproSmart: App-guided lateral flow self-test for remote monitoring of patients with chronic inflammatory bowel disease (IBD), including Ulcerative Colitis and Crohn's disease. Includes Self-Test, Office, and RUO variants.
- CalproLab
- Easy Extract
Products and services
- CalproSmart Self-Test (CAL201, CAL230, CAL240, CAL250) App-guided lateral flow self-test for remote monitoring of patients with chronic inflammatory bowel disease (Ulcerative Colitis and Crohn's disease). Enables patients to test at home and securely share quantitative fecal calprotectin results (77–1500 mg/kg) with their clinical team via smartphone app, supporting proactive flare detection. CE/IVD marked.
- CalproSmart Office (CAL220)
Quantifiable outcome
- 94% sensitivity for CalproSmart Self-Test vs. laboratory ELISA
- +5 more outcomes
Companies that use Calpro
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Calpro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
Feature6 records
Calpro partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Creonate (UK)coreCreonate, a UK-based lateral flow manufacturer, merged with Calpro in 2025. Creonate operates one of Europe's largest lateral flow facilities with capacity of 2 million tests per day. The merger brought significant manufacturing scale and created the combined EkteDx family, strengthening Calpro's global production capabilities and innovation pipeline.
- EkteDxcoreEkteDx is the parent company formed by the merger of Calpro and Creonate in 2025. The EkteDx family combines discovery, production, and commercialization to ensure supply security and rapid innovation in precision diagnostics. EkteDx operates from Bedford Technology Park, UK, and supports Calpro's international operations.
- Svar Life Science GroupcoreCalpro became part of Svar Life Science Group in 2017, strengthening global presence and research capabilities. Svar Life Science's Malmö (Sweden) facility specializes in immunoassay and diagnostic technology supporting advanced clinical and research applications. The group relationship provides cross-functional research and commercial synergies.
- TrioLab OYminorRegional distributor covering Finland and the Baltic states for Calpro's calprotectin diagnostic products.
- SelinionminorRegional distributor covering Benelux for Calpro's calprotectin diagnostic products.
- Menarini (Spain)minorRegional distributor covering Spain for Calpro's calprotectin diagnostic products.
- Hibernian Medical (Ireland)minorRegional distributor covering Ireland for Calpro's calprotectin diagnostic products.
- Tanigen (Czech Republic)minorRegional distributor covering Czech Republic for Calpro's calprotectin diagnostic products.
- ISCARE Clinic (Czech Republic)minorHealthcare clinic using CalproSmart Self-Test as part of a telemedicine platform for remote IBD monitoring. Remote care using CalproSmart achieved public health insurance reimbursement in Czech Republic from 2022, serving as a landmark case study demonstrating clinical and economic value of remote calprotectin monitoring.
- Global Pharmaceutical PartnersminorCalpro supplies calprotectin biomarker tools to pharmaceutical companies requiring robust diagnostic tools for clinical trials, drug development, and biomarker programs. Products used include CalproLab RUO kits for research and CalproSmart RUO for remote patient monitoring in clinical studies.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Calpro competitors and assessment
Company assessmentDirect peers
- R-Biopharm: German IVD manufacturer with a calprotectin (CALEX/RIDASCREEN calprotectin) ELISA and extraction device portfolio. Directly overlaps CalproLab ELISA and Easy Extract on the laboratory workflow, serving the same hospital and reference lab customers across Europe.
- Eagle Biosciences: US IVD developer/distributor offering calprotectin and other gastroenterology biomarker assays. Competes with CalproLab and CalproSmart in North American research and clinical lab channels, often through OEM/distribution partnerships.
- Bühlmann Laboratories: Swiss specialist and the dominant incumbent in fecal calprotectin testing, offering both laboratory ELISA (EK-CAL) and point-of-care/rapid calprotectin assays. Directly competes with CalproLab ELISA and CalproSmart on the same biomarker, customer base (gastroenterology labs and clinics), and clinical guidelines.
- AESKU.Diagnostics: German IVD manufacturer with an inflammation and gastroenterology ELISA menu including calprotectin assays. Competes with CalproLab in European hospital and reference lab channels and shares a distributor-driven go-to-market model.
- EKF Diagnostics: Wales-based diagnostics group with a QuikRead fecal calprotectin point-of-care product and related IVD menu. Competes with CalproSmart Office in clinic/POC settings and shares the same gastroenterology and primary care buyer base.
- ALPCO Diagnostics: US-based IVD developer with a focused fecal calprotectin ELISA portfolio targeting gastroenterology research and clinical labs. Competes head-to-head with CalproLab ELISA in the US and offers a comparable single-biomarker value proposition for IBD differentiation and monitoring.
- SENTINEL Diagnostics: Italian IVD manufacturer with a calprotectin ELISA and broader inflammatory/autoimmune menu. Competes with CalproLab ELISA in European hospital labs and shares distributor-led GTM motion in Southern Europe.
- Demeditec Diagnostics: German IVD distributor and manufacturer with a calprotectin ELISA portfolio. Overlaps CalproLab ELISA in the European laboratory channel, particularly Germany and DACH, and operates a comparable distributor-driven commercial model.
- Epitope Diagnostics: US-based ELISA kit manufacturer with a fecal calprotectin assay (KT-849) and adjacent IBD biomarker menu. Competes with CalproLab ELISA in research and clinical labs, particularly in North America and APAC.
Broad incumbents
- ORGENTEC Diagnostika: German specialty IVD company (part of the Sebia/Aarebus group historically) with a broad autoimmune and inflammation menu including calprotectin assays. Competes with Calpro in the laboratory segment but serves a much wider biomarker portfolio across hospital labs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Calpro social profiles
Digital presenceCalpro compliance and trust
Trust signalCompliance3 records
Calpro financial estimates
Financial estimateRevenue estimate
Valuation estimate
Calpro leadership team
Management profileNumber of profiles
Profiles4 records
Calpro subsidiaries and ownership
Company hierarchySubsidiaries1 record
Calpro funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Calpro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Calpro
What does Calpro do?
Calpro develops, manufactures, and distributes CE/IVD-marked calprotectin diagnostic test kits and a connected digital ecosystem for inflammatory bowel disease (IBD). The portfolio includes laboratory ELISA kits (CalproLab ALP and HRP), point-of-care rapid tests (CalproSmart Office), home self-tests (CalproSmart Self-Test), research-use-only variants, a prefilled stool extraction device (Calpro Easy Extract), and the CalproSmart digital platform (app, cloud backend, API, and DeepLink integration to HIS/LIMS). Products deliver quantitative fecal calprotectin results in under 20 minutes across the full IBD care pathway.
Is Calpro a public or private company?
Calpro is a private company. It is classified as corporate owned and is currently operating.
When was Calpro founded?
Calpro was founded in 1993. It employs 1 to 10 people.
Where is Calpro based?
Calpro is headquartered in Lysaker, Norway, in the Europe region.
How does Calpro make money?
Four revenue lines are on record. Diagnostic Test Kits and Laboratory Assays are the primary driver. The others are easy Extract Extraction Devices, calproSmart Digital Services and Integration and distribution Partnerships.
Who are Calpro's main competitors?
Direct peers on record are R-Biopharm, Eagle Biosciences, Bühlmann Laboratories, AESKU.Diagnostics, EKF Diagnostics, ALPCO Diagnostics, SENTINEL Diagnostics, Demeditec Diagnostics and Epitope Diagnostics. ORGENTEC Diagnostika is listed as a broad incumbent.
Does Calpro have an API?
Yes. Secure API integration connecting CalproSmart data to Hospital Information Systems (HIS) and Laboratory Information Management Systems (LIMS) platforms. Enables automatic data transfer, real-time insights in existing systems, and streamlined clinician workflows. Alternative DeepLink integration allows app-in-app embedding within third-party applications for unified user experience without duplicate data storage. Developer documentation is at calpro.no/calprosmart-services.
What industry is Calpro in?
Calpro's product category is In Vitro Diagnostics for Inflammatory Bowel Disease (Calprotectin Testing). Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.